METABOLISM 润色咨询

METABOLISM-CLINICAL AND EXPERIMENTAL

出版年份：1952 年文章数：2036 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：9.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2026-01-03 ms8000002977722179 来自上海

    偏重的研究方向：脂质代谢临床转化
    经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；
    24年10.10投稿
    10.15with editor
    10.20送审
    12.15 大修（需补临床样本验证+机制补充）
    25年1.20 修回
    2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月
    聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2024-08-08 COCO-么么哒 来自四川省

    投稿命中率:25.0
    经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收
    感恩编辑，审稿人的付出

    21

    展开21条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2025-04-03 GISL 来自重庆

    这个with editor多久呀？

    10

    展开10条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2024-06-29 ms8000000757755021 来自广东省

    爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2025-12-01 1249edb9m40(暂无昵称) 来自湖北省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：糖尿病
    经验分享：11月19日 提交后立马with editor
    12月1日 DIP后拒稿
    邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2025-09-13 ms6000001626382996 来自广东省

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享：2024.11 under reivew
    2025.3 rejcet 审稿意见不是很差
    2025.3-2025.7 按拒稿意见修改后重投
    2025.7-2025.9 under review 审稿意见非常积极
    2025.9 reject 拒稿理由是研究疾病受众面太小。

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2025-08-29 1130106087 来自广东省

    With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2025-08-23 ms7000000965463315 来自北京

    下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2022-05-22 嘻嘻哈哈623

    审稿速度:6.0 | 投稿命中率:25.0
    偏重的研究方向：糖尿病
    经验分享：2021.12.22投稿
    2022.2.28返修， reject with revision
    2022.3.31一修回去
    2022.5.2返修回来， accept with revision
    2022.5.16二修回去
    2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。

    9

    展开9条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2295773, encodeId=b6f32295e7393, content=偏重的研究方向：脂质代谢临床转化<br>经验分享：整体审稿还是比较高效，录用率约 50%、国人发文占比高；<br>24年10.10投稿<br>10.15with editor<br>10.20送审<br>12.15 大修（需补临床样本验证+机制补充）<br>25年1.20 修回<br>2.6接收，审稿人很专业，修回后无二次审稿，全程约3个多月<br>聚焦人类代谢疾病（糖尿病、肥胖、脂肪肝等）的临床/转化研究，基础研究需体现明确临床意义等方向的可尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722179, createdTime=Sat Jan 03 23:53:23 CST 2026, time=2026-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2219063, encodeId=84fe2219063d2, content=投稿命中率:25.0<br>经验分享：2024.5.5 投稿，当晚送审；2024.6.3 大修；2024.7.1修回；2024.7.31小修；2024.8.5修回；2024.8.6接收<br>感恩编辑，审稿人的付出, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Thu Aug 08 09:31:49 CST 2024, time=2024-08-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2258863, encodeId=7a722258863a0, content=这个with editor多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Thu Apr 03 00:26:26 CST 2025, time=2025-04-03, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212374, encodeId=78e022123e4c6, content=爱思唯尔的状态跟踪显示邀请审稿人了10多天了但一个接受审稿的都么有 ，啥情况，这个级别杂志不应该啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f995638061, createdName=ms8000000757755021, createdTime=Sat Jun 29 21:48:47 CST 2024, time=2024-06-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2291447, encodeId=654b229144efb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：11月19日 提交后立马with editor<br>12月1日 DIP后拒稿<br>邮件里副主编给了点评，并建议Transfer Diabetes Research and Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbe22501895, createdName=1249edb9m40(暂无昵称), createdTime=Mon Dec 01 23:54:51 CST 2025, time=2025-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2281102, encodeId=1889228110214, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：2024.11 under reivew <br>2025.3 rejcet 审稿意见不是很差<br>2025.3-2025.7 按拒稿意见修改后重投<br>2025.7-2025.9 under review 审稿意见非常积极<br>2025.9 reject 拒稿理由是研究疾病受众面太小。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=54585435334, createdName=ms6000001626382996, createdTime=Sat Sep 13 12:15:48 CST 2025, time=2025-09-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2279149, encodeId=ccf122e914960, content=With editors要多久才会变成UR，投稿三天了没动静，如果要拒希望编辑不要拖太久，有没有大佬分享一下经验😥🫣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79202869253, createdName=1130106087, createdTime=Fri Aug 29 07:57:15 CST 2025, time=2025-08-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2278364, encodeId=3e1222e8364c4, content=下午五点投稿，晚上十点拒稿（建议转投Endocrine Practice）。一点也不耽误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43158608917, createdName=ms7000000965463315, createdTime=Sat Aug 23 00:23:29 CST 2025, time=2025-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1221632, encodeId=f3db12216321b, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：糖尿病<br>经验分享：2021.12.22投稿<br>2022.2.28返修， reject with revision<br>2022.3.31一修回去<br>2022.5.2返修回来， accept with revision<br>2022.5.16二修回去<br>2022.5.20accept。总体速度很快，意见很专业，只要返修回来了好好回复意见没问题的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Sun May 22 20:00:46 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2228843, encodeId=38e5222884371, content=偏重的研究方向：肝肠轴;SGLT2;肠道菌群<br>经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Wed Oct 02 09:23:15 CST 2024, time=2024-10-02, status=1, ipAttribution=北京)]
    2024-10-02 ms4000000706495698 来自北京

    偏重的研究方向：肝肠轴;SGLT2;肠道菌群
    经验分享：10.1下午投稿，立刻with editor，今天发现已经under review了！真的非常快速，本来抱着试一试的态度，没想到过了编辑关，希望一切顺利！

    4

    展开4条回复
共206条页码: 1/21页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分